Tumor mutation burden and PIK3CA mutations are associated with pathological complete response in human epidermal growth factor receptor 2-positive breast cancer patients receiving pyrotinib combined with trastuzumab neoadjuvant treatment.

Qiyun Shi,Juncheng Xuhong,Jia Ge,Feng Liu,Yang Lan,Yi Zhang,Tao Luo,Xiu-wu Bian,Xiaowei Qi,Jun Jiang

Tumor mutation burden and PIK3CA mutations are associated with pathological complete response in human epidermal growth factor receptor 2-positive breast cancer patients receiving pyrotinib combined with trastuzumab neoadjuvant treatment.

2021

Qiyun Shi
Juncheng Xuhong
Jia Ge
Feng Liu
Yang Lan
Yi Zhang
Tao Luo
Xiu-wu Bian
Xiaowei Qi
Jun Jiang

e12610Background: Our previous study reported a good efficacy and safety of pyrotinib combined with trastuzumab neoadjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive bre...

Keywords:

Cancer research
Medicine
Mutation (genetic algorithm)
neoadjuvant treatment
Breast cancer
Human Epidermal Growth Factor Receptor 2
Pathological
complete response
Trastuzumab

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations